NMP22 Bladder CheckÆ Test for Monitoring Bladder Cancer

The NMP22 Bladder Check TestÆ is used in the diagnosis and monitoring of bladder cancer. NAS will allow coverage and payment for this test when used to monitor bladder cancer between cystourethroscopy intervals, effective for dates of service on or after September 19, 2011. For claim payment, use the following codes: • 88299 – Unlisted cytogenetic study, adding the description “NMP22” in Item 19 of the CMS-1500 form or the electronic equivalent. For Part A claims, add this notation to the remarks screenÖ.and • V10.51 – Personal history of malignant neoplasm of bladder.

Source: https://www.noridianmedicare.com/cgi-bin/coranto/viewnews.cgi?id=EFEApyppEucrVDdNWy&tmpl=part_a_viewnews&style=part_ab_viewnews